142 related articles for article (PubMed ID: 36794010)
1. Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3.
Yu X; Yan J; Li Y; Cheng J; Zheng L; Fu T; Zhu Y
Food Nutr Res; 2023; 67():. PubMed ID: 36794010
[TBL] [Abstract][Full Text] [Related]
2. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
Eskra JN; Schlicht MJ; Bosland MC
Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
[TBL] [Abstract][Full Text] [Related]
3. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
[TBL] [Abstract][Full Text] [Related]
4. The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.
Yin YD; Fu M; Brooke DG; Heinrich DM; Denny WA; Jamieson SM
Front Oncol; 2014; 4():159. PubMed ID: 24995161
[TBL] [Abstract][Full Text] [Related]
5. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
6. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
Chen J; Yang Y; Xu D; Li J; Wu S; Jiang Y; Wang C; Yang Z; Zhao L
Biochem Biophys Res Commun; 2021 Feb; 540():83-89. PubMed ID: 33450484
[TBL] [Abstract][Full Text] [Related]
7. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
8. [Geinsten inhibits the proliferation of VCaP castration-resistant prostate cancer cells].
Li F; Zhu YF; Chen JY; Zhou J; He YQ; Yu XP
Zhonghua Nan Ke Xue; 2016 Dec; 22(12):1065-1070. PubMed ID: 29282909
[TBL] [Abstract][Full Text] [Related]
9. Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
Miyazaki Y; Teramoto Y; Shibuya S; Goto T; Okasho K; Mizuno K; Uegaki M; Yoshikawa T; Akamatsu S; Kobayashi T; Ogawa O; Inoue T
J Clin Med; 2019 May; 8(5):. PubMed ID: 31052459
[TBL] [Abstract][Full Text] [Related]
10. Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Endo S; Oguri H; Segawa J; Kawai M; Hu D; Xia S; Okada T; Irie K; Fujii S; Gouda H; Iguchi K; Matsukawa T; Fujimoto N; Nakayama T; Toyooka N; Matsunaga T; Ikari A
J Med Chem; 2020 Sep; 63(18):10396-10411. PubMed ID: 32847363
[TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
12. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
13. siAKR1C3@PPA complex nucleic acid nanoparticles inhibit castration-resistant prostate cancer in vitro.
Cui X; Yao Z; Zhao T; Guo J; Ding J; Zhang S; Liang Z; Wei Z; Zoa A; Tian Y; Li J
Front Oncol; 2022; 12():1069033. PubMed ID: 36591491
[TBL] [Abstract][Full Text] [Related]
14. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
[TBL] [Abstract][Full Text] [Related]
16. A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
Fokidis HB; Yieng Chin M; Ho VW; Adomat HH; Soma KK; Fazli L; Nip KM; Cox M; Krystal G; Zoubeidi A; Tomlinson Guns ES
J Steroid Biochem Mol Biol; 2015 Jun; 150():35-45. PubMed ID: 25797030
[TBL] [Abstract][Full Text] [Related]
17. The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer.
Le TT; Hsieh CL; Lin IH; Chu CY; Do AD; Chen SH; Shigemura K; Kitagawa K; Fujisawa M; Liu MC; Chen KC; Sung SY
Am J Cancer Res; 2022; 12(1):176-197. PubMed ID: 35141012
[TBL] [Abstract][Full Text] [Related]
18. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism.
Sekine Y; Nakayama H; Miyazawa Y; Kato H; Furuya Y; Arai S; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Oncol Lett; 2018 Mar; 15(3):3167-3172. PubMed ID: 29435052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
